<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(4)</volume><submitter>Yuan L</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>B7-H6 is a novel co-stimulatory protein exclusively expressed on a variety of cancer cells and associated with poor prognosis. T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive hematological malignancy whose treatment requires reliable prognostic biomarkers and therapeutic targets. However, the rare nature and delayed progression of T-LBL have limited its clinical management.&lt;h4>Methods&lt;/h4>The expression of B7-H6 was analyzed by immunohistochemistry (IHC) in 65 T-LBL samples; the association with the clinicopathological characteristics and prognosis was also investigated. B7-H6-depleted Jurkat cells were also generated to investigate the effect of B7-H6 on cell proliferation, migration, and invasion. RNA sequencing was used to explore differentially expressed</pubmed_abstract><journal>Annals of translational medicine</journal><pagination>328</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7944329</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>B7-H6 is a new potential biomarker and therapeutic target of T-lymphoblastic lymphoma.</pubmed_title><pmcid>PMC7944329</pmcid><pubmed_authors>Sun L</pubmed_authors><pubmed_authors>Jing H</pubmed_authors><pubmed_authors>Ke X</pubmed_authors><pubmed_authors>Yuan L</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Yang S</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>B7-H6 is a new potential biomarker and therapeutic target of T-lymphoblastic lymphoma.</name><description>&lt;h4>Background&lt;/h4>B7-H6 is a novel co-stimulatory protein exclusively expressed on a variety of cancer cells and associated with poor prognosis. T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive hematological malignancy whose treatment requires reliable prognostic biomarkers and therapeutic targets. However, the rare nature and delayed progression of T-LBL have limited its clinical management.&lt;h4>Methods&lt;/h4>The expression of B7-H6 was analyzed by immunohistochemistry (IHC) in 65 T-LBL samples; the association with the clinicopathological characteristics and prognosis was also investigated. B7-H6-depleted Jurkat cells were also generated to investigate the effect of B7-H6 on cell proliferation, migration, and invasion. RNA sequencing was used to explore differentially expressed</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Feb</publication><modification>2025-04-04T19:24:15.044Z</modification><creation>2025-02-19T01:40:07.826Z</creation></dates><accession>S-EPMC7944329</accession><cross_references><pubmed>33708955</pubmed><doi>10.21037/atm-20-5308</doi></cross_references></HashMap>